Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease
Item
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Files for Download
http://repository.netecweb.org/pdfs/ciw575.pdf
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Document Viewer
Title
Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease
Subject
Description
Since the discovery of Ebola virus in the Democratic Republic of Congo in 1976, outbreaks of EVD had been mainly confined to rural areas (http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html)...
Creator
Date
2016-11-15
Type
Citation
Kraft, C. S. (2016). "Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease." Clin Infect Dis 63(10): 1295-1296.
Accessibility
free online - Oxford Academic
Was this resource helpful?